Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 10/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258171 | 0.84 | LPAR3 (0.63) | SMPD1FDPSGGPS1LPAR3LPAR1 | |
| Phosphoric Acid Monotetradecyl Ester SCHEMBL28355509 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| SCHEMBL28359607 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| Phosphoric Acid Monodecyl Ester SCHEMBL28359660 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| SCHEMBL3784849 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL483790 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL5680624 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL3893034 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| SCHEMBL11255117 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 | |
| SCHEMBL28355945 | 0.79 | LPAR3 (0.59) | LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | FDPS 4666/4885SMPD1 111/4885GGPS1 3007/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | FDPS 4735/4885SMPD1 148/4885GGPS1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.